Blueprint Medicines (BPMC) to Release Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Blueprint Medicines to post earnings of ($0.44) per share and revenue of $158.31 million for the quarter.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, analysts expect Blueprint Medicines to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $88.51 on Tuesday. Blueprint Medicines has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The business has a 50-day moving average of $87.46 and a two-hundred day moving average of $93.18. The stock has a market capitalization of $5.66 billion, a P/E ratio of -81.95 and a beta of 0.75. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of analyst reports. Wolfe Research initiated coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating for the company. Piper Sandler boosted their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Stephens reiterated an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. JPMorgan Chase & Co. lifted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, April 16th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $124.53.

Insider Transactions at Blueprint Medicines

In other news, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.